Literature DB >> 17200419

Uncovering the pharmacology of the G protein-coupled receptor GPR40: high apparent constitutive activity in guanosine 5'-O-(3-[35S]thio)triphosphate binding studies reflects binding of an endogenous agonist.

Leigh A Stoddart1, Andrew J Brown, Graeme Milligan.   

Abstract

In cells lacking expression of Ca(2+)-mobilizing G proteins, coexpression of human GPR40 and Galpha(q) allowed medium- and long-chain fatty acids to elevate intracellular [Ca(2+)]. This was also observed when human embryonic kidney (HEK) 293 cells were transfected with a GPR40-Galpha(q) fusion protein. The kinetic of elevation of intracellular [Ca(2+)] slowed with increasing fatty acid chain length, suggesting different ligand on-rates, whereas the addition of fatty acid-free bovine serum albumin reduced signals, presumably by binding the fatty acids. To allow effective ligand equilibration, GPR40-Galpha(q) was used in guanosine 5'-O-(3-[(35)S]thio)triphosphate ([(35)S]GTPgammaS) binding assays. After expression of GPR40-Galpha(q) in HEK293 cells and membrane preparation basal binding of [(35)S]GTPgammaSinGalpha(q) immunoprecipitates was high and not elevated substantially by fatty acids. However, treatment of membranes with fatty acid-free bovine serum albumin reduced the basal [(35)S]GTPgammaS binding in a concentration-dependent manner and allowed the responsiveness and pharmacology at GPR40 of each of the fatty acids thiazolidinediones and a novel small-molecule agonist to be uncovered. Membranes of rat INS-1E cells that express GPR40 endogenously provided similar observations. The high apparent constitutive activity of GPR40-Galpha(q) was also reversed by a small-molecule GPR40 antagonist, and basal [(35)S]GTPgammaS binding was prevented by the selective Galpha(q)/Galpha(11) inhibitor YM-254890. The current studies provide novel insights into the pharmacology of GPR40 and indicate that G protein-coupled receptors which respond to fatty acids, and potentially to other lipid ligands, can be occupied by endogenous agonists before assay and that this may mask the pharmacology of the receptor and may be mistaken for high levels of constitutive activity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17200419     DOI: 10.1124/mol.106.031534

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  23 in total

1.  Deconvolution of complex G protein-coupled receptor signaling in live cells using dynamic mass redistribution measurements.

Authors:  Ralf Schröder; Nicole Janssen; Johannes Schmidt; Anna Kebig; Nicole Merten; Stephanie Hennen; Anke Müller; Stefanie Blättermann; Marion Mohr-Andrä; Sabine Zahn; Jörg Wenzel; Nicola J Smith; Jesús Gomeza; Christel Drewke; Graeme Milligan; Klaus Mohr; Evi Kostenis
Journal:  Nat Biotechnol       Date:  2010-08-15       Impact factor: 54.908

Review 2.  G protein-coupled receptors as targets for anti-diabetic therapeutics.

Authors:  Da Young Oh; Jerrold M Olefsky
Journal:  Nat Rev Drug Discov       Date:  2016-01-29       Impact factor: 84.694

3.  Thiazolidinediones induce osteocyte apoptosis by a G protein-coupled receptor 40-dependent mechanism.

Authors:  Aleksandra Mieczkowska; Michel F Baslé; Daniel Chappard; Guillaume Mabilleau
Journal:  J Biol Chem       Date:  2012-05-16       Impact factor: 5.157

4.  Extracellular loop 2 of the free fatty acid receptor 2 mediates allosterism of a phenylacetamide ago-allosteric modulator.

Authors:  Nicola J Smith; Richard J Ward; Leigh A Stoddart; Brian D Hudson; Evi Kostenis; Trond Ulven; Joanne C Morris; Christian Tränkle; Irina G Tikhonova; David R Adams; Graeme Milligan
Journal:  Mol Pharmacol       Date:  2011-04-15       Impact factor: 4.436

Review 5.  Characterizing pharmacological ligands to study the long-chain fatty acid receptors GPR40/FFA1 and GPR120/FFA4.

Authors:  G Milligan; E Alvarez-Curto; K R Watterson; T Ulven; B D Hudson
Journal:  Br J Pharmacol       Date:  2015-02-27       Impact factor: 8.739

6.  The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

Review 7.  Hunting for the function of orphan GPCRs - beyond the search for the endogenous ligand.

Authors:  Raise Ahmad; Stefanie Wojciech; Ralf Jockers
Journal:  Br J Pharmacol       Date:  2014-12-15       Impact factor: 8.739

8.  G Protein-coupled Receptor 40 (GPR40) and Peroxisome Proliferator-activated Receptor γ (PPARγ): AN INTEGRATED TWO-RECEPTOR SIGNALING PATHWAY.

Authors:  Shuibang Wang; Keytam S Awad; Jason M Elinoff; Edward J Dougherty; Gabriela A Ferreyra; Jennifer Y Wang; Rongman Cai; Junfeng Sun; Anetta Ptasinska; Robert L Danner
Journal:  J Biol Chem       Date:  2015-06-23       Impact factor: 5.157

9.  The action and mode of binding of thiazolidinedione ligands at free fatty acid receptor 1.

Authors:  Nicola J Smith; Leigh A Stoddart; Nicola M Devine; Laura Jenkins; Graeme Milligan
Journal:  J Biol Chem       Date:  2009-04-27       Impact factor: 5.157

Review 10.  Lipid receptors and islet function: therapeutic implications?

Authors:  M A Kebede; T Alquier; M G Latour; V Poitout
Journal:  Diabetes Obes Metab       Date:  2009-11       Impact factor: 6.577

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.